HIV-1 gp120 vaccine induces affinity maturation in both new and persistent antibody clonal lineages

scientific article published on 2 May 2012

HIV-1 gp120 vaccine induces affinity maturation in both new and persistent antibody clonal lineages is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1128/JVI.00426-12
P932PMC publication ID3416280
P698PubMed publication ID22553329
P5875ResearchGate publication ID224889057

P50authorBarton HaynesQ4865631
Robert J ParksQ122828591
Joy PickeralQ125314693
Xi ChenQ131376777
Guido FerrariQ56481169
Garnett KelsoeQ60614752
David C. MontefioriQ63302725
Georgia D. TomarasQ63663866
M Anthony MoodyQ73297881
R Ryan MeyerhoffQ82266912
Hua-Xin LiaoQ88608388
Ruijun ZhangQ88772991
Munir AlamQ89520930
Nicole YatesQ90167585
Andrew FoulgerQ114423499
Joshua EudaileyQ114426430
Justin PollaraQ114519514
Thaddeus C GurleyQ114780414
Mark S DrinkerQ117248643
P2093author name stringLu Wang
Gerald Voss
Dawn J Marshall
John F Whitesides
Nathan A Vandergrift
Joshua D Amos
Jae-Sung Yu
Julia Cavanaugh Scull
P2860cites workPolyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individualsQ24635002
Rapid cloning of high-affinity human monoclonal antibodies against influenza virusQ24644672
Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 BindingQ27670829
Base-Calling of Automated Sequencer Traces Using Phred. II. Error ProbabilitiesQ27860615
Base-Calling of Automated Sequencer Traces UsingPhred. I. Accuracy AssessmentQ27860665
Identification of common molecular subsequencesQ27860816
High-throughput quantitative analysis of HIV-1 and SIV-specific ADCC-mediating antibody responsesQ28242631
H3N2 influenza infection elicits more cross-reactive and less clonally expanded anti-hemagglutinin antibodies than influenza vaccinationQ28743596
Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in ThailandQ29547531
Broad neutralization coverage of HIV by multiple highly potent antibodiesQ29615361
Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1Q29619511
Predominant autoantibody production by early human B cell precursorsQ29619656
Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors.Q30371529
Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infectionQ30398435
De Novo Anti-HLA Antibody After Pandemic H1N1 and Seasonal Influenza Immunization in Kidney Transplant RecipientsQ30403833
SoDA: implementation of a 3D alignment algorithm for inference of antigen receptor recombinationsQ33229588
Optimality of mutation and selection in germinal centersQ33598442
Chiropteran types I and II interferon genes inferred from genome sequencing traces by a statistical gene-family assemblerQ33642157
Characteristics of the earliest cross-neutralizing antibody response to HIV-1.Q33798076
Isolation of a monoclonal antibody that targets the alpha-2 helix of gp120 and represents the initial autologous neutralizing-antibody response in an HIV-1 subtype C-infected individualQ33912373
B-cell subsets and the mature preimmune repertoire. Marginal zone and B1 B cells as part of a "natural immune memory".Q33996226
Isolation of a human anti-HIV gp41 membrane proximal region neutralizing antibody by antigen-specific single B cell sortingQ34042758
B-cell-lineage immunogen design in vaccine development with HIV-1 as a case studyQ34273373
HIV vaccines: lessons learned and the way forwardQ34342558
The role of antibody polyspecificity and lipid reactivity in binding of broadly neutralizing anti-HIV-1 envelope human monoclonal antibodies 2F5 and 4E10 to glycoprotein 41 membrane proximal envelope epitopesQ34610233
Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremiaQ34848486
Rapid generation of fully human monoclonal antibodies specific to a vaccinating antigenQ34953172
Is developing an HIV-1 vaccine possible?Q35043547
Role of immune mechanisms in induction of HIV-1 broadly neutralizing antibodiesQ35116581
Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutatedQ35441583
A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary virusesQ35569049
Autoreactivity in human IgG+ memory B cellsQ35729131
Enhanced HIV-1 neutralization by antibody heteroligationQ35735385
Anti-DNA antibodies from autoimmune mice arise by clonal expansion and somatic mutationQ36350233
B-1 and B-2 cell-derived immunoglobulin M antibodies are nonredundant components of the protective response to influenza virus infectionQ36368741
Human immunodeficiency virus type 1 gp41 antibodies that mask membrane proximal region epitopes: antibody binding kinetics, induction, and potential for regulation in acute infectionQ36423897
Strategies for eliciting HIV-1 inhibitory antibodiesQ36452155
Autoreactive IgG memory antibodies in patients with systemic lupus erythematosus arise from nonreactive and polyreactive precursorsQ36775342
Multiple HIV-1-specific IgG3 responses decline during acute HIV-1: implications for detection of incident HIV infectionQ36886845
Influenza vaccination of patients with systemic lupus erythematosus: safety and immunogenecity issuesQ36940173
Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligationQ36977531
Vaccination and autoimmune rheumatic diseasesQ37242804
Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donorsQ37333772
Cross-reactive monoclonal antibodies to multiple HIV-1 subtype and SIVcpz envelope glycoproteinsQ37445549
Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: implications for evasion of immune responses and design of vaccine immunogensQ37456354
Systemic lupus erythematosus and vaccination.Q37459408
Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine?Q37519312
Influenza and autoimmunityQ37598328
Long-term persistence of antibodies induced by vaccination and safety follow-up, with the first combined vaccine against hepatitis A and B in children and adultsQ38460063
SoDA2: a Hidden Markov Model approach for identification of immunoglobulin rearrangementsQ39783279
Strong and persistent CD4+ T-cell response in healthy adults immunized with a candidate HIV-1 vaccine containing gp120, Nef and Tat antigens formulated in three Adjuvant Systems.Q39845365
Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assaysQ39988991
Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies.Q40429324
Affinity Dependence of the B Cell Response to Antigen: A Threshold, a Ceiling, and the Importance of Off-RateQ41027647
High-throughput isolation of immunoglobulin genes from single human B cells and expression as monoclonal antibodiesQ42939116
No evidence of autoimmunity in 6-year-old children immunized at birth with recombinant hepatitis B vaccineQ44047671
Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteersQ48036553
Autoimmune response following annual influenza vaccination in 92 apparently healthy adultsQ51120650
Anti-phospholipid antibodies following vaccination with recombinant hepatitis B vaccineQ51836286
Somatic hypermutation in B cells: an optimal control treatmentQ52390653
Autoimmunity and hepatitis A vaccine in childrenQ64386663
Virgin B cell recruitment and the lifespan of memory clones during antibody responses to 2,4-dinitrophenyl-hemocyaninQ68800085
Control of early viral and bacterial distribution and disease by natural antibodiesQ73257312
Systemic lupus erythematosus following vaccination against 2009 influenza A (H1N1)Q83022393
P433issue14
P407language of work or nameEnglishQ1860
P921main subjectantibodyQ79460
P304page(s)7496-7507
P577publication date2012-05-02
P1433published inJournal of VirologyQ1251128
P1476titleHIV-1 gp120 vaccine induces affinity maturation in both new and persistent antibody clonal lineages
P478volume86

Reverse relations

cites work (P2860)
Q36294782A Shot in the Arm for HIV Prevention? Recent Successes and Critical Thresholds
Q35706462A broad range of mutations in HIV-1 neutralizing human monoclonal antibodies specific for V2, V3, and the CD4 binding site
Q56345991Adjuvant-dependent enhancement of HIV Env-specific antibody responses in infant rhesus macaques
Q36363231Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family
Q54263363Application of area scaling analysis to identify natural killer cell and monocyte involvement in the GranToxiLux antibody dependent cell-mediated cytotoxicity assay
Q58781552Beyond Hot Spots: Biases in Antibody Somatic Hypermutation and Implications for Vaccine Design
Q36290038Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial.
Q92177871Bridging Vaccine-Induced HIV-1 Neutralizing and Effector Antibody Responses in Rabbit and Rhesus Macaque Animal Models
Q37003083Clonal analysis of human anti-V3 monoclonal antibodies selected by a V3 tetramer
Q37130745Cross-neutralizing activity of human anti-V3 monoclonal antibodies derived from non-B clade HIV-1 infected individuals
Q64930831Divergent Primary Immune Responses Induced by Human Immunodeficiency Virus-1 gp120 and Hepatitis B Surface Antigen Determine Antibody Recall Responses.
Q35691113Diverse antibody genetic and recognition properties revealed following HIV-1 envelope glycoprotein immunization
Q35881985Diversity, cellular origin and autoreactivity of antibody-secreting cell population expansions in acute systemic lupus erythematosus
Q34133551Elicitation of HIV-1-neutralizing antibodies against the CD4-binding site.
Q37730206Enhanced antibody responses to an HIV-1 membrane-proximal external region antigen in mice reconstituted with cultured lymphocytes
Q35913910Functional and Structural Characterization of Human V3-Specific Monoclonal Antibody 2424 with Neutralizing Activity against HIV-1 JRFL
Q38631751HIV DNA-Adenovirus Multiclade Envelope Vaccine Induces Gp41 Antibody Immunodominance in Rhesus Macaques
Q38897259HIV-1 Consensus Envelope-Induced Broadly Binding Antibodies
Q40449984HIV-1 Envelope Mimicry of Host Enzyme Kynureninase Does Not Disrupt Tryptophan Metabolism.
Q37059216HIV-1 Neutralizing Antibodies with Limited Hypermutation from an Infant
Q35728947HIV-1 VACCINES. Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies
Q27022055HIV-1 antibodies from infection and vaccination: insights for guiding vaccine design
Q33577972HIV-1 vaccines: challenges and new perspectives
Q27000480HIV‐1 neutralizing antibodies: understanding nature's pathways
Q36905471High-Resolution Longitudinal Study of HIV-1 Env Vaccine-Elicited B Cell Responses to the Virus Primary Receptor Binding Site Reveals Affinity Maturation and Clonal Persistence.
Q35674731Human immunodeficiency virus vaccines
Q45068770Immunisation with foamy virus Bet fusion proteins as novel strategy for HIV-1 epitope delivery
Q37499531Immunization with an SIV-based IDLV Expressing HIV-1 Env 1086 Clade C Elicits Durable Humoral and Cellular Responses in Rhesus Macaques
Q34345369Improved flow-based method for HIV/SIV envelope-specific memory B-cell evaluation in rhesus macaques
Q30395005Influenza immunization elicits antibodies specific for an egg-adapted vaccine strain
Q37221575Initiation of immune tolerance-controlled HIV gp41 neutralizing B cell lineages
Q40135155Interrogation of individual intratumoral B lymphocytes from lung cancer patients for molecular target discovery
Q64053755Kappa chain maturation helps drive rapid development of an infant HIV-1 broadly neutralizing antibody lineage
Q93063721Lessons for general vaccinology research from attempts to develop an HIV vaccine
Q33557844Lessons learned from human HIV vaccine trials
Q92400606Longitudinal Analysis Reveals Early Development of Three MPER-Directed Neutralizing Antibody Lineages from an HIV-1-Infected Individual
Q35824311Mucosal Immunogenicity of Genetically Modified Lactobacillus acidophilus Expressing an HIV-1 Epitope within the Surface Layer Protein
Q34637968Neutralizing Antibody Responses in Macaques Induced by Human Immunodeficiency Virus Type 1 Monovalent or Trivalent Envelope Glycoproteins
Q34057711Nonneutralizing functional antibodies: a new "old" paradigm for HIV vaccines
Q33645528Novel directions in HIV-1 vaccines revealed from clinical trials
Q33821896Probing the Impact of Local Structural Dynamics of Conformational Epitopes on Antibody Recognition
Q38163241Profiling the IgOme: meeting the challenge
Q27693849Progress in HIV-1 vaccine development.
Q30620607Quality control, analysis and secure sharing of Luminex® immunoassay data using the open source LabKey Server platform
Q35973587Rapid Development of gp120-Focused Neutralizing B Cell Responses during Acute Simian Immunodeficiency Virus Infection of African Green Monkeys
Q58721980Rational Design of DNA-Expressed Stabilized Native-Like HIV-1 Envelope Trimers
Q35641498Single-Chain Soluble BG505.SOSIP gp140 Trimers as Structural and Antigenic Mimics of Mature Closed HIV-1 Env.
Q40438707Structure-based Design of Cyclically Permuted HIV-1 gp120 Trimers That Elicit Neutralizing Antibodies
Q33578985T-bet+ B cells are induced by human viral infections and dominate the HIV gp140 response
Q92511306Techniques to Study Antigen-Specific B Cell Responses
Q27680688The Effects of Somatic Hypermutation on Neutralization and Binding in the PGT121 Family of Broadly Neutralizing HIV Antibodies
Q38243948The HIV-1 gp120 V1V2 loop: structure, function and importance for vaccine development
Q38621582The Impact of Poxvirus Vector Priming, Protein Co-Administration, and Vaccine Intervals on HIV gp120 Vaccine-Elicited Antibody Magnitude and Function in Infant Macaques
Q58999852The Problem of Antigen Affinity Discrimination in B-Cell Immunology
Q37469197Tissue memory B cell repertoire analysis after ALVAC/AIDSVAX B/E gp120 immunization of rhesus macaques
Q33612459Vaccine Elicitation of High Mannose-Dependent Neutralizing Antibodies against the V3-Glycan Broadly Neutralizing Epitope in Nonhuman Primates
Q27675879Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2
Q40166335What Are the Primary Limitations in B-Cell Affinity Maturation, and How Much Affinity Maturation Can We Drive with Vaccination? Breaking through Immunity's Glass Ceiling
Q36365309λ Light Chain Bias Associated With Enhanced Binding and Function of Anti-HIV Env Glycoprotein Antibodies

Search more.